1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Pharmaceuticals: Scandinavia Industry Guide

Pharmaceuticals: Scandinavia Industry Guide

  • May 2014
  • -
  • MarketLine
  • -
  • 88 pages

Introduction

The Scandinavian Pharmaceuticals industry guide provides top-line qualitative and quantitative summary information including: market size (value 2009-13, and forecast to 2018). The guide also contains descriptions of the leading companies including key financial metrics and analysis of competitive pressures within the market.

Features and benefits

* Save time carrying out entry-level research by identifying the size, growth, and leading players in the Scandinavian pharmaceuticals market.
* Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the Scandinavian pharmaceuticals market.
* Leading company profiles reveal details of key pharmaceuticals market players' Scandinavian operations and financial performance.
* Add weight to presentations and pitches by understanding the future growth prospects of the Scandinavian pharmaceuticals market with forecasts.
* Compares data from Denmark, Norway and Sweden, alongside individual chapters on each country.

Highlights

The Scandinavian pharmaceuticals market had a total market value of $9.7 billion in 2013. Denmark was the fastest growing country with a CAGR of 2.5% over the 2009-13 period.
Within the pharmaceuticals industry, Sweden is the leading country among the Scandinavian countries, with market revenues of $4.5 billion in 2013. This was followed by Denmark and Norway, with $3.0 and $2.1 billion, respectively.
Sweden is expected to lead the pharmaceuticals in the Scandinavian countries, with a value of $5.2 billion in 2018, followed by Denmark and Norway with expected values of $3.6 and $2.2 billion respectively.

Your key questions answered

* What was the size of the Scandinavian pharmaceuticals market by value in 2013?
* What will be the size of the Scandinavian pharmaceuticals market in 2018?
* What factors are affecting the strength of competition in the Scandinavian pharmaceuticals market?
* How has the market performed over the last five years?

Table Of Contents

Pharmaceuticals: Scandinavia Industry Guide
INTRODUCTION
What is this report about?
Who is the target reader?
How to use this report
Definitions
SCANDINAVIA PHARMACEUTICALS
Industry Outlook
PHARMACEUTICALS IN DENMARK
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Leading companies
Macroeconomic indicators
PHARMACEUTICALS IN NORWAY
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Leading companies
Macroeconomic indicators
PHARMACEUTICALS IN SWEDEN
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Leading companies
Macroeconomic indicators
APPENDIX
Methodology

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
OpportunityAnalyzer: Huntington’s Disease - Opportunity Analysis and Forecast to 2024

OpportunityAnalyzer: Huntington’s Disease - Opportunity Analysis and Forecast to 2024

  • $ 9 495
  • Industry report
  • May 2016
  • by Global Data

OpportunityAnalyzer: Huntington’s Disease - Opportunity Analysis and Forecast to 2024 Summary Huntington’s Disease (HD) is a rare, autosomal-dominant, neurodegenerative disorder, characterized by impaired ...

Asthma Pricing, Reimbursement, and Access

Asthma Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • May 2016
  • by Datamonitor Healthcare

Growth in the asthma market will be fueled by the introduction of new and expensive biologics, but companies will have to navigate access restrictions imposed by payers concerned about budget impact. This ...

Multiple Myeloma Pricing, Reimbursement, and Access

Multiple Myeloma Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • May 2016
  • by Datamonitor Healthcare

Growth in the multiple myeloma market will be spurred by the approval of novel drugs and the increasing role of combination therapy, but risk-sharing agreements will be key to entry into increasingly restrictive ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.